XBP1 and acute lymphoblastic leukemia: Moreover, we determined levels of total, spliced and unspliced variants of XBP1 in BCP-ALL and T-ALL xenograft samples and correlated them to the cytotoxicity of bortezomib, with the aim to assess if total or spliced XBP1 may serve as a marker of better response to bortezomib in ALL patients.